[go: up one dir, main page]

DK1667993T3 - Heteroaryl-substituerede 1,3-dihydroindol-2-on-derivater og lægemidler indeholdende dem - Google Patents

Heteroaryl-substituerede 1,3-dihydroindol-2-on-derivater og lægemidler indeholdende dem Download PDF

Info

Publication number
DK1667993T3
DK1667993T3 DK04765719.2T DK04765719T DK1667993T3 DK 1667993 T3 DK1667993 T3 DK 1667993T3 DK 04765719 T DK04765719 T DK 04765719T DK 1667993 T3 DK1667993 T3 DK 1667993T3
Authority
DK
Denmark
Prior art keywords
dihydro
oxo
indol
carboxylic acid
methoxy
Prior art date
Application number
DK04765719.2T
Other languages
English (en)
Inventor
Wilfried Lubisch
Wilfried Hornberger
Thorsten K Oost
Daryl Richard Sauer
Liliane Unger
Wolfgang Wernet
Hervé Geneste
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Application granted granted Critical
Publication of DK1667993T3 publication Critical patent/DK1667993T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (19)

1. Forbindelse med formlen (I)
(i) i hvilken A er en aromatisk heteromonocyklisk, eller en aromatisk eller partielt aromatisk heterobicyclisk ring, hvor de heterocykliske ringe er 5- eller 6-leddede ringe og indeholder op til 4 heteroatomer valgt fra gruppen bestående af N, O og S, og op til 2 oxogrupper, hvor højst ét af heteroatomerne er et oxygenatom, og A kan være substitueret med substituenter R11, R12 og/eller R13, hvor R11, R12 og R13 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R3 og R4 er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, O-C1-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, eller R3 og R4 er forbundet til dannelse af -CH=CH-CH=CH-, -(CH2)4- eller -(CH2)3‘, R5 er en substituent (W)-(X)-(Y)-Z, hvor W er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-al-kynylen, O, 0-(Ci-C4-alkylen), S, S-(Ci-C4-alkylen), NR54, NR54-(Ci-C4-alkylen) og en binding, X er valgt fra gruppen bestående af CO, CO-O, SO2, NR54, NR54-CO, NR54-S02, CO-NR58 og en binding, Y er Ci-Ce-alkylen, C2-C6-alkenylen, C2-C6-alkynylen eller en binding, Z er valgt fra gruppen bestående af hydrogen, E, O-R52, NR51R52, S-R52, hvor E er en umættet, mættet eller partielt umættet mono-, bi- eller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, hvilken ring kan indeholde op til to oxogrupper og kan være substitueret med substituenter R55, R56, R57 og/eller op til tre substituenter R53, R51 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, C2-Ce-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R53, R52 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C-i-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, E og Ci-C4-alkylen-E, R53 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, C-i-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R54 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-Ce-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R59, R55 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, phenyl, Ci-C4-alkylen-phenyl, hvor ringen kan være substitueret med op til to substituenter R60, og OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R56 er en gruppe Q1-Q2-Q3, hvor Q1 er valgt fra gruppen bestående af en binding, Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-alkynylen, Ci-C4-alkylen-N(Ci-C4-alkyl), N(Ci-C4-alkyl), Ci-C4-alkylen-NH, NH, N(Ci-C4-alkyl)-Ci-C4-alkylen, NH-Ci-C4-alkylen, O, Ci-C4-alkylen-0, O-C1-C4-alkylen, CO-NH, CO-N(Ci-C4-aJkyl), NH-CO, N(Ci-C4-alkyl)-CO, CO, SO2, SO, S, O, SO2-NH, S02-N(Ci-C4-alkyl), NH-SO2, N(Ci-C4-alkyl)-S02, O-CO-NH, 0-C0-N(Ci-C4-alkyl), NH-CO-O, N(Ci-C4-alkyl)-C0-0, N(Ci-C4-alkyl)-CO-N(Ci-C4-alkyl), NH-CO-N(Ci-C4-alkyl), N(Ci-C4-alkyl)-CO-NH og NH-CO-NH, Q2 er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-alky-nylen og en binding, Q3 er et hydrogenatom eller en umættet, mættet eller partielt umættet mono-, bieller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, og som kan indeholde op til to oxo-grupper og kan være substitueret med substituenterne R63, R64 og/eller R65, R57 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, phenyl, Ci-C4-alkylen-phenyl, COOH, C0-0-Ci-C4-alkyl, CONH2, CO-NH-Ci-C4-alkyl, CO-N(Ci-C4-alkyl)2, CO-Ci-C4-alkyl, CH2-NH2, CH2-NH-C1-C4-alkyl og CH2-N(Ci-C4-alkyl)2, R58 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R62, R59, R60 og R62 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R63, r64 0g R65 j hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R6 og R7 er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, O-C1-C4-alkylen-phenyl, phenyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, og dens tautomere former, enantiomere og diastereomere former og de fysiologisk tolererede salte deraf.
2. Forbindelse ifølge krav 1, i hvilken A er valgt fra gruppen bestående af aromatisk heteromonocykliske og aromatisk heterobicykliske systemer indeholdende 1 eller 2 heteroatomer, hvor ét af de 2 heteroatomer er nitrogen.
3. Forbindelse ifølge krav 1, i hvilken A er valgt fra gruppen bestående af ben-zothiazol, pyrimidin, pyridin, pyridazin, pyrazin, isoquinolin, quinolin, thiazol, ben-zimidazol, imidazol, benzoxazol, benzothiophen, thiophen, benzofuran og furan.
4. Forbindelse med formlen (II)
(II) i hvilken B er valgt fra gruppen bestående af thiophen, furan, pyrrol, pyridin, quinolin, tetra-hydroquinolin, isoquinolin, tetrahydroisoquinolin, benzothiophen, benzofuran, dihydrobenzofuran, indol, dihydroisoindol, en aromatisk heteromonocyklisk og en aromatisk eller partielt aromatisk hetero-bicyklisk ring, hvor de heterocykliske ringe er 5- eller 6-leddede ringe og indeholder 2 til 4 he-teroatomer valgt fra gruppen bestående af N, O og S, og op til 2 oxogrupper, og B kan være substitueret med substituenterne R21, R22 og/eller R23, R21, R22 og R23 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, morpholin-4-yl, pyrro-lidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4-(Ci-C4-alkyl)-piperazin-1-yl, R3 og R4 er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, O-C1-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, eller R3 og R4 er forbundet til dannelse af -CH=CH-CH=CH-, -(CH2)4- eller -(CH2)3', R5 er en gruppe (W)-(X)-(Y)-Z, hvor W er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-al-kynylen, O, 0-(Ci-C4-alkylen), S, S-(Ci-C4-alkylen), NR54, NR54-(Ci-C4-alkylen) og en binding, X er valgt fra gruppen bestående af CO, CO-O, SO2, NR54, NR54-CO, NR54-S02, CO-NR58 og en binding, Y er Ci-Ce-alkylen, C2-C6-alkenylen, C2-C6-alkynylen eller en binding, Z er valgt fra gruppen bestående af hydrogen, E, O-R52, NR51R52, S-R52, hvor E er en umættet, mættet eller partielt umættet mono-, bi- eller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, hvilken ring kan indeholde op til to oxogrupper og kan være substitueret med substituenter R55, R56, R57 og/eller op til tre substituenter R53 og R51 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, C2-Ce-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R53, R52 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C-i-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, E og Ci-C4-alkylen-E, R53 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, C-i-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R54 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R59, R55 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, phenyl, Ci-C4-alkylen-phenyl, hvor ringen kan være substitueret med op til to substituenter R60, og OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R56 er en gruppe Q1-Q2-Q3, hvor Q1 er valgt fra gruppen bestående af en binding, Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-alkynylen, Ci-C4-alkylen-N(Ci-C4-alkyl), N(Ci-C4-alkyl), Ci-C4-alkylen-NH, NH, N(Ci-C4-alkyl)-Ci-C4-alkylen, NH-Ci-C4-alkylen, O, Ci-C4-alkylen-0, O-C1-C4-alkylen, CO-NH, CO-N(Ci-C4-alkyl), NH-CO, N(Ci-C4-alkyl)-CO, CO, SO2, SO, S, O, SO2-NH, S02-N(Ci-C4-alkyl), NH-SO2, N(Ci-C4-alkyl)-S02, O-CO-NH, 0-C0-N(Ci-C4-alkyl), NH-CO-O, N(Ci-C4-alkyl)-C0-0, N(Ci-C4-alkyl)-CO-N(Ci-C4-alkyl), NH-CO-N(Ci-C4-alkyl), N(Ci-C4-alkyl)-CO-NH og NH-CO-NH, Q2 er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-al-kynylen og en binding, Q3 er et hydrogenatom eller en umættet, mættet eller partielt umættet mono-, bieller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, og som kan indeholde op til to oxo-grupper og kan være substitueret med substituenterne R63, R64 og/eller R65, R57 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, phenyl, Ci-C4-alkylen-phenyl, COOH, C0-0-Ci-C4-alkyl, CONH2, CO-NH-Ci-C4-alkyl, CO-N(Ci-C4-alkyl)2, CO-Ci-C4-alkyl, CH2-NH2, CH2-NH-C1-C4-alkyl og CH2-N(Ci-C4-alkyl)2, R58 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R62, R59, R60 og R62 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R63, R64 og R65 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, O-C1-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R6 og R7 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-Ce-al-kynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, og dens tautomere former, enantiomere og diastereomere former og de fysiologisk tolererede salte deraf.
5. Forbindelse ifølge krav 4, i hvilken B er valgt fra gruppen bestående af thio-phen, furan, pyrrol, pyrazol, isoxazol, pyridin, pyrimidin, quinolin, isoquinolin, tetrahydroisoquinolin, benzothiophen, benzofuran, indol, imidazol, thiazol, imida-zothiazol, benzoxazin og quinoxalin.
6. Forbindelse med formlen (III),
(Ill) i hvilken D er en aromatisk heteromonocyklisk, eller en aromatisk eller partielt aromatisk heterobicyklisk ring, hvor de heterocykliske ringe er 5- eller 6-leddede ringe og indeholder op til 4 heteroatomer valgt fra gruppen bestående af N, O og S, og op til 2 oxogrupper, og D kan være substitueret med substituenter R21, R22 og/eller R23, G er en aromatisk heteromonocyklisk, aromatisk eller partielt aromatisk heterobicyklisk ring, hvor de heterocykliske ringe er 5- eller 6-leddede ringe og indeholder op til 4 heteroatomer valgt fra gruppen bestående af N, O og S, og op til 2 oxogrupper, og G kan være substitueret med substituenter R71, R72 og/eller R73, R21, R22, R23, R71, R72 og R73 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-Ce-alkyl, C2-Ce-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4-(Ci-C4-alkyl)-piperazin-1-yl, R3 og R4 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-al-kynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, eller R3 og R4 er forbundet til dannelse af -CH=CH-CH=CH-, -(CH2)4‘ eller -(CH2)3‘, R5 er en gruppe (W)-(X)-(Y)-Z, hvor W er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-al-kynylen, O, 0-(Ci-C4-alkylen), S, S-(Ci-C4-alkylen), NR54, NR54-(Ci-C4-alkylen) og en binding, X er valgt fra gruppen bestående af CO, CO-O, SO2, NR54, NR54-CO, NR54-S02, CO-NR58 og en binding, Y er Ci-Ce-alkylen, C2-C6-alkenylen, C2-C6-alkynylen eller en binding, Z er valgt fra gruppen bestående af hydrogen, E, O-R52, NR51R52, S-R52, hvor E er en umættet, mættet eller partielt umættet mono-, bi- eller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, og som kan omfatte op til to oxogrupper, og E kan være substitueret med substituenter R55, R56, R57 og/eller op til tre substituenter R53, R51 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R53, R52 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, E og Ci-C4-alkylen-E, R53 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OH, 0-Ci-C4-alkyl, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R54 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phe-nylringen kan være substitueret med op til to substituenter R59, R55 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl, Ci-C4-alkylen-phenyl, hvor ringen kan være substitueret med op til to substituenter R60, og OH, 0-Ci-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R56 er en gruppe Q1-Q2-Q3, hvor Q1 er valgt fra gruppen bestående af en binding, Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-alkynylen, Ci-C4-alkylen-N(Ci-C4-alkyl), N(Ci-C4-alkyl), Ci-C4-alkylen-NH, NH, N(Ci-C4-alkyl)-Ci-C4-alkylen, NH-Ci-C4-alkylen, O, Ci-C4-alkylen-0, O-C1-C4-alkylen, CO-NH, CO-N(Ci-C4-alkyl), NH-CO, N(Ci-C4-alkyl)-CO, CO, SO2, SO, S, O, SO2-NH, S02-N(Ci-C4-alkyl), NH-SO2, N(Ci-C4-alkyl)-S02, O-CO-NH, 0-C0-N(Ci-C4-alkyl), NH-CO-O, N(Ci-C4-alkyl)-C0-0, N(Ci-C4-alkyl)-CO-N(Ci-C4-alkyl), NH-CO-N(Ci-C4-alkyl), N(Ci-C4-alkyl)-CO-NH og NH-CO-NH, Q2 er valgt fra gruppen bestående af Ci-C4-alkylen, C2-C4-alkenylen, C2-C4-al-kynylen og en binding, Q3 er et hydrogenatom eller en umættet, mættet eller partielt umættet mono-, bieller tricyklisk ring med højst 14 carbonatomer og 0 til 5 nitrogenatomer, 0 til 2 oxygenatomer og/eller 0 til 2 svovlatomer, og som kan omfatte op til to oxogrup-per og kan være substitueret med substituenterne R63, R64 og/eller R65, R57 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-Ce-alkyl, phenyl, Ci-C4-alkylen-phenyl, COOH, C0-0-Ci-C4-alkyl, CONH2, CO-NH-Ci-C4-alkyl, CO-N(Ci-C4-alkyl)2, CO-Ci-C4-alkyl, CH2-NH2, CH2-NH-C1-C4-alkyl og CH2-N(Ci-C4-alkyl)2, R58 i hver forekomst er uafhængigt valgt fra gruppen bestående af hydrogen, C1-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl og Ci-C4-alkylen-phenyl, hvor phenyl ri ngen kan være substitueret med op til to substituenter R62, R59, R60 og R62 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OFI, O-C1-C4-alkyl, C-i-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NFI2, NFI(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, R63, R64 og R65 i hver forekomst er valgt uafhængigt af hinanden fra gruppen bestående af hydrogen, chlor, brom, iod, fluor, CN, CF3, OCF3, NO2, OFI, O-C1-C4-alkyl, O-phenyl, 0-Ci-C4-alkylen-phenyl, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(Ci-C4-alkyl) og N(Ci-C4-alkyl)2, og dens tautomere former, enantiomere og diastereomere former og de fysiologisk tolererede salte deraf.
7. Forbindelse ifølge krav 6, i hvilken D er valgt fra gruppen bestående af aromatisk heteromonocykliske og aromatisk heterobicykliske systemer indeholdende 1 eller 2 heteroatomer, hvor ét af de 2 heteroatomer er nitrogen.
8. Forbindelse ifølge krav 6, i hvilken D er valgt fra gruppen bestående af ben-zothiazol, pyrimidin, pyridin, pyridazin, pyrazin, isoquinolin, quinolin, thiazol, ben-zimidazol, imidazol, benzoxazol, benzothiophen, thiophen, benzofuran og furan.
9. Forbindelse ifølge ethvert af kravene 6 til 8, i hvilken G er valgt fra gruppen bestående af thiophen, furan, pyrrol, pyrazol, isoxazol, pyridin, pyrimidin, qui-nolin, isoquinolin, tetrahydroisoquinolin, benzothiophen, benzofuran, indol, imida-zol, thiazol, imidazothiazol, benzoxazin og quinoxalin.
10. Forbindelse valgt fra (2S,4R)-1 -[3-benzothiazol-2-yl-5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, højredrejende diastereomer, (2S,4R)-1 -[3-benzothiazol-2-yl-5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2,4-dimethoxy-pyrimi-din-5-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2,4-dimethoxy-pyrimi-din-5-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, højredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, højredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methyl-pyridin-3-yl)- 2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-chlorpyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methoxy-pyridin-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(4-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(4-methyl-pyridin-3-yl)- 2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-pyrazin-2-yl-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methoxy-pyrazin-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3,6-dimethoxy-pyrida-zin-4-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(isoquinolin-4-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(quinolin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(thiazol-2-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(1 -methyl-1 H-ben-zimidazol-2-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxyl-syre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(1 -methyl-1 H-imidazol- 2-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(benzoxazol-2-yl)-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-benzo[b]thio-phen-2-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-thiophen-2-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(benzo[b]thiophen-7-yl)-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(benzofuran-7-yl)-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(benzofuran-2-yl)-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-furan-2-yl)- oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-furan-3-yl-oxo-2,3-dihy-dro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihy-dro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-3-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(5-chlor-thiophen-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[1 -(3-brom-5-chlor-thiophen-2-sulfonyl)-5-chlor-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (2S,4R)-1 -[1 -(4-brom-5-chlor-thiophen-2-sulfonyl)-5-chlor-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, (2S,4R)-1 -[5-chlor-1 -(5-methyl-thiophen-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-1 -(4,5-dichlor-thiophen-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-1 -(3-methylbenzo[b]thiophen-2-sulfonyl)-3-(2-methoxyphe-nyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, (2S,4R)-1 -[1 -(benzo[b]thiophen-2-sulfonyl)-5-chlor-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(5-chlor-3-methyl-benzo[b]thiophen-2-sulfonyl)-3-(2-meth-oxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxyl-syre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)- 2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(1,2-dimethyl-1 H-imidazol-4-sulfonyl)-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-1 -(5-chlor-1,3-dimethyl-1 H-pyrazol-4-sulfonyl)-3-(2-meth-oxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxyl-syre-dimethylamid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(1,3,5-trimethyl-1 H-pyrazol- 4-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(5-methyl-1 -phenyl-1 H-pyrazol-4-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(3,5-dimethyl-isoxazol-4-sulfonyl)-3-(2-methoxy-phenyl)- 2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethyl-thiazol-5-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-1 -(6-chlor-imidazo[2,1-b]thiazol-5-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(pyridin-2-sulfonyl)-2,3-dihy-dro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(5-brom-pyridin-2-sulfonyl)-5-chlor-3-(2-methoxy-phenyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-1 -(5-trifluor-methyl-pyridin-2-sulfonyl)-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[5-chlor-1 -(5-methoxy-pyridin-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(5-chlor-pyridin-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[1 -(5-brom-3-methyl-pyridin-2-sulfonyl)-5-chlor-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(3,5-dimethyl-pyridin-2-sulfonyl)-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(pyridin-3-sulfonyl)-2,3-dihy-dro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(6-morpholin-4-yl-pyridin-3-sulfo-nyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(6-phenoxy-pyridin-3-sulfo-nyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid- trifluoracetat, - (2S,4R)-1 -[5-chlor-1 -(6-methoxypyridin-3-sulfonyl)-3-(2-methoxyphenyl)-2-oxo- 2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(5-brom-6-chlorpyridin-3-sulfonyl)-3-(2-methoxy-phenyl)- 2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyl-amid, (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(4-methyl-3,4-dihydro-2H-benzo-[1,4]oxazin-7-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(1,2,3,4-tetrahydro-isoquino-lin-7-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-hydroxy-3-(3-methyl-thiophen-2-yl)-1,3-dihydro-indol-2-on, - (4-chlor-phenyl)-carbaminsyre-5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 5-chlor-3-hydroxy-3-(2-methoxy-phenyl)-1 -(quinolin-8-sulfonyl)-1,3-dihydro-in-dol-2-on, - piperidin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sul-fonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-pyridin-4-yl-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinoli n-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, 3,4,5,6-tetrahydro-2H-[4,4']bipyridinyl-1-carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-pyridin-2-yl-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-dimethoxy-benzensul-fonyl)-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-pyridin-2-yl-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-dimethoxy-benzensul-fonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-pyridin-2-yl-piperazin-1-carboxylsyre-5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-pyridin-4-yl-piperazin-1-carboxylsyre-5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-pyridin-2-yl-piperazin-1-carboxylsyre-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-pyridin-4-yl-piperazin-1-carboxylsyre-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 3.4.5.6- tetrahydro-2H-[4,4']bipyridinyl-1-carboxylsyre-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phe-nyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -benzensulfonyl-5-chlor- 3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - N-[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-acetamid, 3.4.5.6- tetrahydro-2H-[1,4']bipyridinyl-4-carboxylsyre-[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, 3.4.5.6- tetrahydro-2H-[1,4']bipyridinyl-4-carboxylsyre-[5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - (E)-N-[5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-3-pyridin-4-yl-acrylamid, - (E)-N-[3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihydro-1 H-in-dol-3-yl]-3-pyridin-4-yl-acrylamid, - 3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-carboxylsyre-[5-chlor-1 -(2,4-dimetho-xy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-amid, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, 4-methyl-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinoli n-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, - dimethyl-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sul-fonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - [1,4']bipiperidinyl-1 '-carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quino-lin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-1 -benzensulfonyl-5-chlor- 3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-2-oxo-3-pyridin-2-yl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,4-dimethoxy-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-1 -(2,4-dimethoxy-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-5-methyl-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,4-dimethoxy-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-5-methyl-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,4-dimethoxy-benzen-sulfonyl)-5-methoxy-3-(2-methyl-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2-fluor-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4-fluor-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4-cyano-ben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(3-methoxyben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4-methoxyben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2-chlorbenzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(3-chlor-benzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4-chlorbenzen-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-difluor-ben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4-isopropyl-ben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(3,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-2-oxo-1 -(4-trifluormethyl-benzensulfonyl)-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-2-oxo-1-(4-trifluormethoxy-benzensulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - dimethyl-carbaminsyre-3-benzofuran-7-yl-5-chlor-1-(2,4-dimethoxy-benzensul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[3-(2-ethoxy-phenyl)-5-methoxy-1-(3-methoxy-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-methoxy-3-(2-methoxy-phenyl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-methoxy-phenyl)-5-methyl-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-3-(2-methoxy-phenyl)-5-methyl-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-methoxy-phenyl)-5-methyl-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-3-(2-methoxy-phenyl)-5-methyl-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-methyl-2-oxo-1 -(thio-phen-2-sulfonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-5-methyl-2-oxo-1 -(thio-phen-2-sulfonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[3-(2-methoxy-phenyl)-5-methyl-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-2-oxo-1 -(pyridin- 2-sulfonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-2-oxo-1 -(thio-phen-2-sulfonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-fluor-3-(2-methoxy-phe-nyl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidi n-4-yl)-piperazin-1 -carboxylsyre-5-methoxy-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)-2-oxo-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-methoxy-3-(2-methoxy-phenyl)-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-methoxy-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-ethoxy-phe-nyl)-1-(3-methoxy-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-ethoxy-phe-nyl)-1-(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(thiophen-3-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-chlor-3-(2-ethoxy-phe-nyl)-1-(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-amid, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-fluor-1-(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, (2-diethylamino-ethyl)-methyl-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-chlor-3-(2-ethoxy-phe-nyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-3-(2-ethoxy-phe-nyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-methoxy-3-(2-methoxy-pyridin-3-yl)-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-5-methoxy-3-(2-methoxy-pyridin-3-yl)-2-oxo-1-(pyridin-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-3-(2-methoxy-pyr-idin-3-yl)-2-oxo-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(4,5-dichlor-thio-phen-2-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(5-chlor-thio-phen-2-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidi n-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(1,2-dimethyl-1 H-imidazol-4-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol- 3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-1-(4-methyl-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-1-(5-methyl-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-1 -(2,5-dimethyl-thi-ophen-3-sulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(benzo[b]thiophen-3-sul-fonyl)-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-pyri-din-3-yl)-2-oxo-1-(thiophen-3-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(benzo[b]thiophen-2-sul-fonyl)-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-5-chlor-3-(3-methyl-thio-phen-2-yl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-chlor-3-(3-methyl-thio-phen-2-yl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - benzyl-methyl-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-benzyl-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quin-olin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-methyl-piperazin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(thio-phen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - pyridin-4-yl-methyl-carbaminsyre-5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, benzyl-carbaminsyre-5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - pyridin-4-yl-methyl-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(thio-phen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, (3-imidazol-1 -yl-propyl)-carbaminsyre-5-chlor-1 -(2,4-dimethoxy-benzensul-fonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, (3-morpholin-4-yl-propyl)-carbaminsyre-5-chlor-1-(2,4-dimethoxy-benzensul-fonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-benzoylamino-piperidin-1-carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 3-phenyl-piperidin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quin-olin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 1,3-dihydro-isoindol-2-carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinoli n-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, - 4-phenyl-piperidin-1 -carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quin-olin-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, (2-diethylamino-ethyl)-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinoli n-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, (2-dimethylamino-ethyl)-carbaminsyre-5-chlor-3-(3-methyl-thiophen-2-yl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-methyl-piperazin-1 -carboxylsyre-5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-pyridin-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - dimethyl-carbaminsyre-5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-pyridin-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - (2-pyridin-4-yl-ethyl)-carbaminsyre-5-chlor-3-(3-methyl-thiophen-2-yl)-2-oxo-1-(quinoli n-8-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl-ester, 6-methoxy-3,4-dihydro-1 H-isoquinolin-2-carboxylsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, (4-cyano-thiazol-2-yl-methyl)-carbaminsyre-5-chlor-3-(2-methoxy-phenyl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - dimethyl-carbaminsyre-5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-1-(quin-olin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-isopropyl-piperazin-1-carboxylsyre-5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)- 2- oxo-1-(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, (5-dimethylamino-pentyl)-carbaminsyre-1-benzensulfonyl-5-chlor-3-(2-meth-oxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(2-morpholin-4-yl-ethyl)-piperazin-1 -carboxylsyre-1 -benzensulfonyl-5-chlor- 3- (2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(2-imidazol-1 -yl-ethyl)-piperazin-1 -carboxylsyre-1 -benzensulfonyl-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-benzofuran-7-yl-5-chlor- 1-(2,4-dimethoxy-benzensulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-2-oxo-1 -(thiophen-2-sul-fonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, 4-(4-methyl-piperazin-1 -yl)-piperidin-1 -carboxylsyre-2-oxo-1 -(thiophen-2-sul-fonyl)-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,4-dimethyl-thiazol-5-sulfonyl)-5-methoxy-2-oxo-3-o-tolyl-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,5-dimethyl-thiophen- 3-sulfonyl)-3-(2-isopropoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-isopropoxy-phenyl)-5-methoxy-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,5-dimethyl-thiophen- 3-sulfonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,5-dimethyl-thiophen- 3-sulfonyl)-5-methoxy-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1 H-indol-3-yl-es-ter, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-methoxy-2-oxo-3-(2-propoxy-phenyl)-1-(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-fluor-1 -(1 -methyl-1 H-imidazol-4-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(1,2-dimethyl-1 H-imid-azol-4-sulfonyl)-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-2,3-dihydro-1 H-indol-3-yl-es-ter, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(3,5-dimethyl-isoxazol-4-sulfonyl)-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,5-dimethyl-thiophen- 3- sulfonyl)-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-3-(2-ethoxy-phenyl)-5-fluor-1-(3-methoxy-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-1 -(2,4-dimethyl-thiazol-5-sulfonyl)-3-(2-ethoxy-phenyl)-5-fluor-2-oxo-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[1 -(3,5-dimethyl-isoxazol- 4- sulfonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[1 -(5-chlor-thiophen-2-sul-fonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1 H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[1 -(2,5-dimethyl-thiophen-3-sulfonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-amid, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-5-cyano-3-(2-ethoxy-phe-nyl)-2-oxo-1-(thiophen-3-sulfonyl)-2,3-dihydro-1 H-indol-3-yl-ester, - 4-(1 -methyl-piperidin-4-yl)-piperazin-1 -carboxylsyre-[5-cyano-3-(2-ethoxy-phe-nyl)-2-oxo-1-(thiophen-3-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-amid, - (S)-2-{[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-propionamid, venstredrejende diastereomer, - (S)-2-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl-amino]-N,N-dimethyl-propionamid, venstredre jende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methyl-pyridin-2-yl)- 2- oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -benzensulfonyl-5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihy-dro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-2-oxo-3-(2-oxo-1,2-dihy-dro-pyridin-3-yl)-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-5-me-thyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid-fumarat, venstredrejende diastereomer, - (2S,4R)-1 -[1 -benzensulfonyl-3-(2-methoxy-pyridin-3-yl)-5-methyl-2-oxo-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-5-methoxy-3-(2-methoxy-pyridin- 3- yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -benzensulfonyl-5-methoxy-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-cyano-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (S)-1 -[5-cyano-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(3-methoxy-pyridin-4-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-2-oxo-3-pyridin-2-yl-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-1 -(4-methoxy-benzensul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-piperidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2,6-dimethoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-ethoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid venstredrejende diastereomer, - (2S,4R)-1 -[5-cyano-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-5-iod-3-(3-methoxy-pyrazin-2-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-3-(2,4-dimethoxy-pyrimidin-5-yl)- 5-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 5-trifluormethoxy-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-2,5-dihydro-1H-pyrrol-2-carboxylsyre-dimethyla-mid, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-pyrrolidin-2-carboxylsyre-methyl-ester, - (S)-1 -[5-chlor-3-(6-chlor-2-methoxy-pyridin-3-yl)-1 -(2,4-dimethoxy-benzensul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[1 -(benzo[b]thiophen-3-sulfonyl)-5-chlor-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(2-methyl-1,2,3,4-tetrahydro-iso-quinolin-7-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-car-boxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(4-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(6-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-fluor-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2- oxo-2,3-dihydro-1 H-indol-3-yl]-azetidin-2-carboxylsyre-dimethylamid, venstre drejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-phenyl)-1 -(3-methoxy-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-5-methyl-2-oxo-1 -(pyridin-2-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-5-methyl-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-5-methyl-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-4-hydroxy-1 -[5-methoxy-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(pyridin-2-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-4-hydroxy-1 -[5-methoxy-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereo mer, (2S,4R)-4-hydroxy-1 -[5-methoxy-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyri-din-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dime-thylamid, (2S,4R)-1 -[5-chlor-3-(2,6-dimethoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sul-fonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-1 -(thiophen-2-sul-fonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-1 -(5-methyl-pyridin-2-sul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, venstredrejende diastereomer, (2S,4R)-4-hydroxy-1 -[5-iod-3-(3-methoxy-pyrazin-2-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihyd ro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-4-hydroxy-1 -[5-iod-3-(3-methoxy-pyrazin-2-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-1 -(3-methoxy-thiophen-2-sul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, venstredrejende diastereomer, - (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-1 -(3-methoxy-thiophen-2-sul-fonyl)-2-oxo-5-trifluormethoxy-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxyl-syre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-2-oxo-1 -(quinolin-8-sul-fonyl)-2,3-dihyd ro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(quinolin-8-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-1 -(5-methyl-pyridin-2-sul-fonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, venstredrejende diastereomer, - 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-3-pyrroli-din-1 -yl-1,3-dihydro-indol-2-on, 5-chlor-3-(1,3-dihyd ro-isoindol-2-yl)-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-1,3-dihydro-indol-2-on, 5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-((R)-3-hydroxy-pyrrolidin-1 -yl)-3-(2-methoxy-pyridin-3-yl)-1,3-dihydro-indol-2-on, - 3-amino-5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)- 1.3- dihydro-indol-2-on, - (2S,4R)-4-hydroxy-1 -[3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)- 2.3- dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - 5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-((S)-2-methoxymethyl-pyrrolidin-1 -yl)-3-(2-methoxy-pyridin-3-yl)-1,3-dihydro-indol-2-on, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-amid, venstredrejende diastereomer, - 2-{[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-acetamid, - 2-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl-amino]-N,N-dimethyl-acetamid, - (2S,4R)-1 -[5-chlor-3-(3-methyl-pyridin-2-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-1 -(5-methyl-pyridin-2-sulfonyl)-3-(3-methyl-pyridin-2-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-3-((S)-2-trifluormethyl-pyrrolidin-1 -yl)-1,3-dihydro-indol-2-on, venstredrejende diastereomer, - 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-3-((S)-2-pyrrolidin-1 -ylmethyl-pyrrolidin-1 -yl)-1,3-dihydro-indol-2-on, venstredrejende dia-stereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-pyrrolidin-2-carboxylsyre-tert-butyl-ester, venstredrejende diastereomer, - 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-3-[(S)-2-(4-methyl-piperazin-1 -carbonyl)-pyrrolidin-1 -yl]-1,3-dihydro-indol-2-on, venstredrejende diastereomer, - (S)-4-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-3-dimethylcarbamoyl-piperazin-1-carboxylsyre-tert-butyl-ester, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-ethoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-piperazin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - 5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-3-[(S)-2-(pyrrolidin-1 -carbonyl)-pyrrolidin-1 -yl]-1,3-dihydro-indol-2-one, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2,4-dimethoxy-pyrimidin-5-yl)-1 -(3-methoxy-thiophen-2-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-methylamid, - 1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-3-carboxylsyre-dimethylamid, - 5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-dimethylamino-1 -methyl-ethyla-mino)-3-(2-methoxy-pyridin-3-yl)-1,3-dihydro-indol-2-on, venstredrejende diastereomer, (S)-1 -[5-cyano-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-2-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylamino]-N,N-dimethyl-butyramid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2,6-dimethoxy-pyridin-3-yl)-1 -(4-methoxy-benzensul-fonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-di-methylamid, venstredrejende diastereomer, 1 -[5-cyano-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, - (2S,4R)-1 -[5-chlor-3-(2-ethoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-dihy-dro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[5-chlor-3-(2-ethoxy-phenyl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-cyano-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-2-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (2S,4R)-1 -[5-cyano-3-(2-methoxy-phenyl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, (2S,4R)-1 -[3-(2-ethoxy-phenyl)-5-methoxy-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, - (2S,4R)-1 -[5-cyano-3-(2-methoxy-phenyl)-2-oxo-1 -(thiophen-3-sulfonyl)-2,3-di-hydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethylamid, (S)-2-{[5-cyano-1-(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-propionamid, - (S)-2-{[5-cyano-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-propionamid, - (S)-2-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2- oxo-2,3-dihydro-1 H-indol-3-yl-amino]-3,N,N-trimethyl-butyramid, venstre drejende diastereomer, (S)-1 -[5-cyano-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-piperidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (S)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-piperidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-4-hydroxy-1 -[1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-5-trifluormethoxy-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (S)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - 2-[5-chlor-1-(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-ylamino]-2,N,N-trimethyl-propionamid, - (2S,4R)-1 -[5-cyano-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-cyano-1 -(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-cyano-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, (2S,4R)-1 -[5-chlor-3-(2-ethoxy-pyridin-3-yl)-1 -(4-methoxy-benzensulfonyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dimethyla-mid, - (S)-2-{[5-chlor-1-(4-methoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-propionamid, venstredrejende diastereomer, - (S)-2-{[5-chlor-3-(2-methoxy-pyridin-3-yl)-1-(5-methyl-pyridin-2-sulfonyl)-2-oxo- 2.3- dihydro-1 H-indol-3-yl]-methyl-amino}-N,N-dimethyl-propionamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-3-(2-methoxy-pyridin-3-yl)-1 -(5-methyl-pyridin-2-sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethylamid, venstredrejende diastereomer, 3-[(S)-2-(azetidin-1 -carbonyl)-pyrrolidin-1 -yl]-5-chlor-1 -(2,4-dimethoxy-ben-zensulfonyl)-3-(2-methoxy-pyridin-3-yl)-1,3-dihydro-indol-2-on, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-pyrrolidin-2-carboxylsyre-ethyl-methyl-amid, venstredrejende diastereomer, - (2S,4S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-methoxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (25.45) -1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-phenoxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (25.45) -1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-methoxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-phenoxy-pyrrolidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4,4-difluor-pyrrolidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (2S,4R)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-piperidin-2-carboxylsyre-dime-thylamid, venstredrejende diastereomer, (2S,4S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-fluor-piperidin-2-carboxylsyre-dimethyla-mid, venstredrejende diastereomer, - (S)-1 -[5-chlor-1 -(2,4-dimethoxy-benzensulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4,4-difluor-piperidin-2-carboxylsyre-dimethyl-amid, venstredrejende diastereomer og de fysiologisk tolererede salte deraf.
11. Lægemiddel indeholdende en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf.
12. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling og/eller forebyggelse af forskellige vasopressin-afhængige eller oxytocin-afhængige sygdomme.
13. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af depressioner og/eller bipolære lidelser såsom fx dysthymiske lidelser, subsyndromal depression, sæsonafhængige lidelser, præmenstruelle dysphoriske lidelser og/eller psykotiske lidelser.
14. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af angst- og/eller stressrelaterede lidelser såsom fx generelle angstlidelser, paniske lidelser, obsessive-kompulsive lidelser, post-traumatiske lidelser, akutte stresslidelser og/eller social fobi.
15. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af hukommelseslidelser og/eller Alzheimers sygdom.
16. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af psykoser og/eller psykotiske lidelser.
17. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af Cushings syndrom.
18. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 10, en tautomer form, en enantiomer form, en diastereomer form og/eller et fysiologisk tolereret salt deraf til fremstilling af et lægemiddel til behandling af stofrelaterede lidelser.
19. Anvendelse ifølge krav 18, hvor de stofrelaterede lidelser er valgt fra lidelser i forbindelse med alkoholindtagelse og alkohol-inducerede lidelser.
DK04765719.2T 2003-09-30 2004-09-30 Heteroaryl-substituerede 1,3-dihydroindol-2-on-derivater og lægemidler indeholdende dem DK1667993T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/675,300 US20050070718A1 (en) 2003-09-30 2003-09-30 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PCT/EP2004/010940 WO2005030755A1 (en) 2003-09-30 2004-09-30 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

Publications (1)

Publication Number Publication Date
DK1667993T3 true DK1667993T3 (da) 2015-10-05

Family

ID=34377107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04765719.2T DK1667993T3 (da) 2003-09-30 2004-09-30 Heteroaryl-substituerede 1,3-dihydroindol-2-on-derivater og lægemidler indeholdende dem

Country Status (14)

Country Link
US (4) US20050070718A1 (da)
EP (4) EP1667993B1 (da)
JP (3) JP4684229B2 (da)
CA (1) CA2537598C (da)
CY (1) CY1116730T1 (da)
DK (1) DK1667993T3 (da)
ES (1) ES2547642T3 (da)
HR (1) HRP20151025T1 (da)
HU (1) HUE025419T2 (da)
MX (1) MXPA06003558A (da)
PL (1) PL1667993T3 (da)
SI (1) SI1667993T1 (da)
TW (1) TW200526640A (da)
WO (1) WO2005030755A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2007056341A1 (en) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2006072458A2 (de) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2006080574A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
EP1861392A2 (de) 2005-03-24 2007-12-05 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014904A1 (de) * 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
WO2007052517A1 (ja) * 2005-10-31 2007-05-10 Sumitomo Chemical Company, Limited ヒドロキシ－２－ピロリジンカルボキシアミド化合物の製法
EP1957480A1 (de) 2005-12-02 2008-08-20 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2659364T3 (es) 2006-04-07 2018-03-15 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
DE102006040915A1 (de) * 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
JP5437070B2 (ja) 2006-08-26 2014-03-12 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換ベンゾイミダゾロン誘導体、それを含む薬剤およびそれの使用
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008080971A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
RU2461556C2 (ru) * 2006-12-30 2012-09-20 Эбботт Гмбх Унд Ко. Кг Замещенные производные оксидола и их применение в качестве лигандов рецептора вазопрессина
WO2008080972A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor modulator
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
PL2114921T3 (pl) * 2006-12-30 2013-05-31 Abbott Gmbh & Co Kg Podstawiona pochodna oksindolu i jej zastosowanie jako liganda receptora wazopresyny
WO2008107399A1 (en) * 2007-03-02 2008-09-12 Abbott Gmbh & Co. Kg Substituted oxindole compounds
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2009071691A2 (de) * 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Oxindol-derivate und ihre verwendung als medikament
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2623504A1 (de) 2007-12-07 2013-08-07 Abbott GmbH & Co. KG 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
PT2639223T (pt) * 2007-12-07 2017-05-08 Vertex Pharma Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos
KR20100097195A (ko) * 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
MX2010006202A (es) * 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
AU2008342569B2 (en) * 2007-12-27 2014-01-16 AbbVie Deutschland GmbH & Co. KG Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) * 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
CN102245573B (zh) 2008-02-28 2013-11-20 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
US20110059983A1 (en) * 2009-06-10 2011-03-10 Abbott Gmbh & Co. Kg Use of substituted oxindole derivatives for the treatment and prophylaxis of pain
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
ES2579965T3 (es) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
CA2811192C (en) 2010-10-01 2018-02-27 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
CN103380125B (zh) 2010-12-21 2015-11-25 拜耳知识产权有限责任公司 制备三嗪基取代的羟吲哚的方法
MX346799B (es) * 2010-12-21 2017-03-31 Bayer Ip Gmbh Metodo para la produccion de oxindoles sustituidos en el n con sulfonilo.
KR101998442B1 (ko) 2011-10-27 2019-07-09 다이쇼 세이야꾸 가부시끼가이샤 아졸 유도체
RU2640420C2 (ru) 2011-11-08 2018-01-09 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
RU2014143794A (ru) 2012-03-30 2016-05-27 Тайсо Фармасьютикал Ко., Лтд. Производное конденсированного азола
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
US9273036B2 (en) 2013-03-14 2016-03-01 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
WO2014140186A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US9862704B2 (en) 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
US9840495B2 (en) 2013-12-20 2017-12-12 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6
UA124567C2 (uk) 2014-04-15 2021-10-13 Вертекс Фармасьютикалз Інкорпорейтед Фармацевтичні композиції для лікування захворювань, опосередкованих муковісцидозним регулятором трансмембранної провідності
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
WO2016099727A2 (en) 2014-12-19 2016-06-23 Dow Corning Corporation Ligand components, associated reaction products, activated reaction products, hydrosilylation catalysts and hydrosilylation curable compositions including the ligand components, and associated methods for preparing same
SG11202012902WA (en) 2018-07-03 2021-01-28 Univ Illinois Activators of the unfolded protein response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
DE102004033834A1 (de) 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
WO2006080574A1 (ja) 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
EP1861392A2 (de) 2005-03-24 2007-12-05 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
US20050070718A1 (en) 2005-03-31
EP1667993A1 (en) 2006-06-14
US20110071156A1 (en) 2011-03-24
SI1667993T1 (sl) 2015-11-30
US7902379B2 (en) 2011-03-08
JP4684229B2 (ja) 2011-05-18
PL1667993T3 (pl) 2015-12-31
JP2011088894A (ja) 2011-05-06
EP2546251A1 (en) 2013-01-16
WO2005030755A1 (en) 2005-04-07
HUE025419T2 (en) 2016-02-29
JP2011102294A (ja) 2011-05-26
CA2537598A1 (en) 2005-04-07
EP1667993B1 (en) 2015-07-01
JP2007507456A (ja) 2007-03-29
CY1116730T1 (el) 2017-03-15
EP2546250A1 (en) 2013-01-16
US8350055B2 (en) 2013-01-08
TW200526640A (en) 2005-08-16
MXPA06003558A (es) 2006-08-31
HK1090044A1 (zh) 2006-12-15
EP2546252A1 (en) 2013-01-16
HRP20151025T1 (hr) 2015-11-06
US20070021607A1 (en) 2007-01-25
CA2537598C (en) 2010-03-09
ES2547642T3 (es) 2015-10-07
US20070185126A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
DK1667993T3 (da) Heteroaryl-substituerede 1,3-dihydroindol-2-on-derivater og lægemidler indeholdende dem
US9487505B2 (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP5363315B2 (ja) 新規ピペラジン、医薬組成物、およびその使用方法
AU2007304475B2 (en) Substituted sulfonamide derivatives
JP5595926B2 (ja) ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
CA2575853A1 (en) Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005261867A1 (en) Substituted oxindol derivatives and medicaments containing the same
KR20120044289A (ko) 치환된 피페리딘
EP2178858A1 (en) Novel heterocyclic compounds as mglu5 antagonists
KR20100031604A (ko) 유로텐신 ｉｉ 수용체 길항제
CA3088827A1 (en) Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US20170050959A1 (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
HK1181041A (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PT1667993E (pt) Derivados de 1,3-di-hidroindol-2-ona substituídos com heteroarilo e medicamentos que os contêm
KR101337163B1 (ko) Ｎｋ3 수용체 길항제로서 퀴나졸린 유도체
HK1090044B (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
HK1181042A (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
HK1181040A (en) Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2010111634A2 (en) Renin inhibitors